WO2002010764A3 - SPECIFIC BINDING AGENTS FOR KSHV vIL-6 THAT NEUTRALIZE A BIOLOGICAL ACTIVITY - Google Patents

SPECIFIC BINDING AGENTS FOR KSHV vIL-6 THAT NEUTRALIZE A BIOLOGICAL ACTIVITY Download PDF

Info

Publication number
WO2002010764A3
WO2002010764A3 PCT/US2001/024179 US0124179W WO0210764A3 WO 2002010764 A3 WO2002010764 A3 WO 2002010764A3 US 0124179 W US0124179 W US 0124179W WO 0210764 A3 WO0210764 A3 WO 0210764A3
Authority
WO
WIPO (PCT)
Prior art keywords
vil
agent
specific binding
kshv
biological activity
Prior art date
Application number
PCT/US2001/024179
Other languages
French (fr)
Other versions
WO2002010764A2 (en
Inventor
Yoshiyasu Aoki
Giovanna Tosato
Original Assignee
Us Health
Yoshiyasu Aoki
Giovanna Tosato
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Yoshiyasu Aoki, Giovanna Tosato filed Critical Us Health
Priority to AU2001278129A priority Critical patent/AU2001278129A1/en
Priority to US10/333,121 priority patent/US6939547B2/en
Publication of WO2002010764A2 publication Critical patent/WO2002010764A2/en
Publication of WO2002010764A3 publication Critical patent/WO2002010764A3/en
Priority to US11/183,336 priority patent/US7108981B2/en
Priority to US11/493,687 priority patent/US7235365B2/en
Priority to US11/803,732 priority patent/US7374756B2/en
Priority to US12/104,326 priority patent/US20080260687A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method for effectiveness the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to receptor component in the absence of the agent. A decrease in the binding of vIL-6 to the receptor component in the presence of the agent indicates that the agent is effective for treating the KSHV-associated disorder.
PCT/US2001/024179 2000-07-31 2001-07-31 SPECIFIC BINDING AGENTS FOR KSHV vIL-6 THAT NEUTRALIZE A BIOLOGICAL ACTIVITY WO2002010764A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2001278129A AU2001278129A1 (en) 2000-07-31 2001-07-31 Specific binding agents for kshv vil-6 that neutralize a biological activity
US10/333,121 US6939547B2 (en) 2000-07-31 2001-07-31 Specific binding agents for KSHV vIL-6 that neutralize a biological activity
US11/183,336 US7108981B2 (en) 2000-07-31 2005-07-14 Specific binding agents for KSHV vIL-6 that neutralize a biological activity
US11/493,687 US7235365B2 (en) 2000-07-31 2006-07-25 Specific binding agents for KSHV vIL-6 that neutralize a biological activity
US11/803,732 US7374756B2 (en) 2000-07-31 2007-05-14 Specific binding agents for KSHV vIL-6 that neutralize a biological activity
US12/104,326 US20080260687A1 (en) 2000-07-31 2008-04-16 SPECIFIC BINDING AGENTS FOR KSHV vIL-6 THAT NEUTRALIZE A BIOLOGICAL ACTIVITY

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22171900P 2000-07-31 2000-07-31
US60/221,719 2000-07-31

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10333121 A-371-Of-International 2001-07-31
US11/183,336 Division US7108981B2 (en) 2000-07-31 2005-07-14 Specific binding agents for KSHV vIL-6 that neutralize a biological activity

Publications (2)

Publication Number Publication Date
WO2002010764A2 WO2002010764A2 (en) 2002-02-07
WO2002010764A3 true WO2002010764A3 (en) 2002-06-06

Family

ID=22829046

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/024179 WO2002010764A2 (en) 2000-07-31 2001-07-31 SPECIFIC BINDING AGENTS FOR KSHV vIL-6 THAT NEUTRALIZE A BIOLOGICAL ACTIVITY

Country Status (3)

Country Link
US (5) US6939547B2 (en)
AU (1) AU2001278129A1 (en)
WO (1) WO2002010764A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
WO2006010041A2 (en) * 2004-07-09 2006-01-26 Eastern Virginia Medical School Morpholino antisense drugs for human herpesvirus 8
DK2990073T3 (en) 2004-11-24 2018-08-13 Bayer Healthcare Llc DEVICES AND SYSTEMS FOR DELIVERING FLUIDS
WO2008085421A2 (en) 2006-12-29 2008-07-17 Medrad, Inc. Patient-based parameter generation systems for medical injection procedures
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
JP5833823B2 (en) 2007-05-21 2015-12-16 アルダーバイオ・ホールディングズ・エルエルシー Antibodies against IL-6 and uses thereof
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
WO2008144757A1 (en) * 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
JP5437240B2 (en) 2007-07-17 2014-03-12 メドラッド インコーポレーテッド Apparatus, system and method for determining parameters of cardiopulmonary function evaluation and fluid delivery procedures
US9421330B2 (en) 2008-11-03 2016-08-23 Bayer Healthcare Llc Mitigation of contrast-induced nephropathy
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
PL2396036T3 (en) 2009-02-13 2017-12-29 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
WO2011066371A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
WO2011032100A1 (en) * 2009-09-11 2011-03-17 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Inhibitors of kshv vil6 and human il6
EP3009455A1 (en) 2009-09-16 2016-04-20 Immunomedics Inc. Class i anti-cea antibodies and uses thereof
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
WO2011068845A1 (en) 2009-12-02 2011-06-09 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
BR112012033116A2 (en) 2010-06-24 2016-10-25 Medrad Inc drug propagation modeling and parameter generation for injection protocols
CA2818813C (en) 2010-11-23 2020-10-06 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of oral mucositis
JP6024025B2 (en) 2011-05-02 2016-11-09 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． Ultrafiltration concentration of allotype-selected antibodies for small volume administration
JP6193978B2 (en) 2012-05-14 2017-09-06 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ System and method for determining drug fluid injection protocol based on x-ray tube voltage
WO2014028560A2 (en) 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
EP2900277B1 (en) 2012-12-13 2022-02-16 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
CA2937236C (en) 2014-02-21 2023-03-07 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
CN106029098A (en) 2014-02-25 2016-10-12 免疫医疗公司 Humanized RFB4 anti-CD22 antibody
CA2953567C (en) 2014-06-24 2023-09-05 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
JP6678941B2 (en) 2014-10-07 2020-04-15 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． Use of neoadjuvant antibody-drug conjugates
JP6746845B2 (en) 2015-04-22 2020-08-26 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． Isolation, detection, diagnosis and/or characterization of circulating TROP-2 positive cancer cells
PL3313443T3 (en) 2015-06-25 2023-11-06 Immunomedics, Inc. Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
SI3316885T1 (en) 2015-07-01 2021-09-30 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
CN106254175A (en) * 2016-07-26 2016-12-21 北京蓝海讯通科技股份有限公司 A kind of cluster detection of anomaly node method, apply and calculating equipment
WO2021021203A1 (en) 2019-07-31 2021-02-04 Halliburton Energy Services, Inc. Methods to monitor a metallic sealant deployed in a wellbore, methods to monitor fluid displacement, and downhole metallic sealant measurement systems
US11761290B2 (en) 2019-12-18 2023-09-19 Halliburton Energy Services, Inc. Reactive metal sealing elements for a liner hanger
US11761293B2 (en) 2020-12-14 2023-09-19 Halliburton Energy Services, Inc. Swellable packer assemblies, downhole packer systems, and methods to seal a wellbore
JPWO2022239720A1 (en) 2021-05-10 2022-11-17
US11879304B2 (en) 2021-05-17 2024-01-23 Halliburton Energy Services, Inc. Reactive metal for cement assurance

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003657A1 (en) * 1996-07-19 1998-01-29 Dade Behring Marburg Gmbh Viral interleukin-6

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801042A (en) 1994-08-18 1998-09-01 The Trustees Of Columbia University In The City Of New York Unique associated Kaposi's sarcoma virus sequences and uses thereof
US5861500A (en) 1996-07-25 1999-01-19 The Trustees Of Columbia University In The City Of New York Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin 6 (IL-6) and uses thereof
US5854398A (en) 1996-07-25 1998-12-29 The Trustees Of Columbia University In The City Of New York Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin 6 (IL-6) and uses thereof
US5948676A (en) 1996-10-10 1999-09-07 The Trustees Of Columbia University In The City Of New York Immediate early protein from Kaposi's sarcoma-associated herpesvirus, DNA encoding same and uses thereof
AU4047897A (en) * 1996-07-25 1998-02-20 Trustees Of Columbia University In The City Of New York, The Unique associated kaposi's sarcoma virus sequences and uses thereof
US5849564A (en) 1996-11-29 1998-12-15 The Trustees Of Columbia University In The City Of New York Polypeptides from Kaposi's sarcoma-associated herpesvirus, DNA encoding same and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003657A1 (en) * 1996-07-19 1998-01-29 Dade Behring Marburg Gmbh Viral interleukin-6

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
K. JONES ET AL.: "Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi' sarcoma herpesvirus-associated infected primary effusion lymphoma cells.", BLOOD, vol. 94, no. 8, 15 October 1999 (1999-10-15), New York, NY, USA, pages 2871 - 2879, XP002193620 *
S. HOISCHEN ET AL.: "Human herpes virus 8 interleukin-6 homologue triggers gp130 on neuronal and hematopoietic cells.", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 267, no. 12, June 2000 (2000-06-01), pages 3604 - 3612, XP002169393 *
Y. AOKI ET AL.: "Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6.", BLOOD, vol. 93, no. 12, 15 June 1999 (1999-06-15), New York, NY, USA, pages 4034 - 4043, XP002193621 *
Y. AOKI ET AL.: "Detection of viral interleukin-6 in Kaposi's sarcoma-associated herpesvirus-linked diseases.", BLOOD, vol. 94, no. 10 suppl. 1 (part 1 of 2), 15 November 1999 (1999-11-15), New York, NY, USA, pages 431a, XP002193619 *
Y. AOKI ET AL.: "Identification of a unique binding site for gp130 in viral interleukin-6 encoded by human herpesvirus 8.", BLOOD, vol. 96, no. 11, 16 November 2000 (2000-11-16), New York, NY, USA, pages 572a, XP002193622 *

Also Published As

Publication number Publication date
US20070015197A1 (en) 2007-01-18
WO2002010764A2 (en) 2002-02-07
US20080260687A1 (en) 2008-10-23
US7374756B2 (en) 2008-05-20
US7235365B2 (en) 2007-06-26
US6939547B2 (en) 2005-09-06
US20030211468A1 (en) 2003-11-13
US7108981B2 (en) 2006-09-19
US20070243162A1 (en) 2007-10-18
AU2001278129A1 (en) 2002-02-13
US20060039927A1 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
WO2002010764A3 (en) SPECIFIC BINDING AGENTS FOR KSHV vIL-6 THAT NEUTRALIZE A BIOLOGICAL ACTIVITY
EP1427377A4 (en) Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate specific membrane antigen
NL300838I2 (en)
DE60133029D1 (en) MEANS FOR THE PREVENTION OR TREATMENT OF PSORIASI
WO2001092340A3 (en) Use of interleukin-4 antagonists and compositions thereof
ATE350060T1 (en) AGENTS FOR PREVENTING OR TREATING PANCREATITIS WHICH CONTAIN ANTI-IL-6 RECEPTOR ANTIBODIES AS THE ACTIVE COMPONENT
HK1071890A1 (en) Spiroazacyclic compounds as monoamine receptor modulators
DE69725484D1 (en) Device for the treatment of urinary incontinence
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
AU7693201A (en) System and method for concentration and load-balancing of requests
ES2159318T3 (en) INHIBITORS OF PROTEIN QUINASA C.
DE69635323D1 (en) Reagent handling method, and device for suppressing the activity reduction of the reagent
ATE173544T1 (en) PARVOVIRUS RECEPTORS AND METHODS OF USE THEREOF
FR2838629B1 (en) DEVICE FOR TREATING URINARY INCONTINENCE
EP1254260A4 (en) Methods for diagnosing and treating heart disease
AU2006902A (en) Methods and instruments for treating pseudoarthrosis
WO2002061430A3 (en) Methods and reagents for treating autoimmune disorders
WO2001044235A3 (en) Agents and methods for the treatment of proliferative diseases
WO2003028536A3 (en) Methods for diagnosing and treating heart disease
WO2002101394A3 (en) Screening method which uses bnpi and dnpi
WO1996001430A3 (en) Screening for nuc inhibitors
NO20004363L (en) Use of D1 / D5 antagonists for the treatment of obsessive-compulsive disorder, somatoform disorders, dissociative disorders, impulse control disorders and autism
WO2003023048A3 (en) METHODS FOR DIAGNOSING AND TREATING DISEASES AND CONDITIONS ASSOCIATED WITH PROTEIN KINASE C$g(l)
WO2004064773A3 (en) Inhibition of e3-ubiquitin ligase hakai for treatment of proliferative disorders
WO2003007800A8 (en) Methods for diagnosing and treating diseases and conditions of the digestive system and cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10333121

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP